Figure 3

Results from a decision-tree sensitivity analysis for the use of FDG-PET to detect extra-hepatic metastases prior to resection of an apparently isolated hepatic metastasis. Using Australian medical costs, the graph plots the incremental cost-accuracy ratio (ICAR: i.e. the additional cost per additional correctly managed patient) against the prevalence of extra-hepatic disease for CT- and PET-based management strategies. PET is more cost-effective if the prevalence is above 0.18. (Typical reported prevalence values are 0.3 or greater).